GenSight Biologics S.A. (EPA:SIGHT)
France · Delayed Price · Currency is EUR 0.0830
+0.0014 (1.72%)
Aug 3, 2026, 2:00 PM CET
GenSight Biologics Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.42 | 2.46 | 2.13 | 10.61 | 44.29 |
Cash & Short-Term Investments | 2.42 | 2.46 | 2.13 | 10.61 | 44.29 |
Cash Growth | -1.99% | 15.46% | -79.89% | -76.04% | 16.72% |
Accounts Receivable | 0 | 0 | 0 | 0 | 0.75 |
Other Current Assets | 2.57 | 2.88 | 4.39 | 12.34 | 8.32 |
Total Current Assets | 4.98 | 5.34 | 6.53 | 22.95 | 53.36 |
Net Property, Plant & Equipment | 0.43 | 0.93 | 2.03 | 2.27 | 2.55 |
Other Intangible Assets | 0 | 0.06 | 0.08 | 0.09 | 0.11 |
Other Long-Term Assets | 2.85 | 4.42 | 0.5 | 0.63 | 0.62 |
Total Assets | 8.26 | 10.76 | 9.13 | 25.94 | 56.65 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.92 | 6.36 | 5.63 | 7.81 | 11.56 |
Current Portion of Long-Term Debt | 3.69 | 13.31 | 17 | 1.54 | 4.68 |
Current Portion of Leases | 0.35 | 0.59 | 0.78 | 0.89 | 0.74 |
Other Current Liabilities | 2.71 | 2.36 | 1.88 | 4.4 | 5.27 |
Total Current Liabilities | 12.67 | 22.62 | 25.29 | 14.64 | 22.24 |
Long-Term Debt | 13.78 | 4.7 | 5.11 | 14.46 | 10.58 |
Long-Term Leases | 0 | 0.51 | 1.05 | 0.97 | 1.51 |
Other Long-Term Liabilities | 6.74 | 9.84 | 8.39 | 11.15 | 6.32 |
Total Long-Term Liabilities | 20.53 | 15.06 | 14.54 | 26.58 | 18.42 |
Total Liabilities | 33.2 | 37.68 | 39.83 | 41.22 | 40.66 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 5.52 | 3.12 | 1.63 | 1.16 | 1.16 |
Additional Paid-in Capital | 217.41 | 206.61 | 190.94 | 181.21 | 181.18 |
Retained Earnings | -247.87 | -236.65 | -223.27 | -197.65 | -166.34 |
Shareholders' Equity | -24.94 | -26.92 | -30.7 | -15.28 | 15.99 |
Total Liabilities & Equity | 8.26 | 10.76 | 9.13 | 25.94 | 56.65 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 17.82 | 19.11 | 23.93 | 17.86 | 17.51 |
Net Cash (Debt) | -15.41 | -16.65 | -21.8 | -7.25 | 26.78 |
Net Cash Growth | - | - | - | - | 42.36% |
Net Cash Per Share | -0.10 | -0.17 | -0.45 | -0.16 | 0.59 |
Book Value | -24.94 | -26.92 | -30.7 | -15.28 | 15.99 |
Book Value Per Share | -0.17 | -0.28 | -0.64 | -0.33 | 0.35 |
Tangible Book Value | -24.94 | -26.98 | -30.78 | -15.37 | 15.88 |
Tangible Book Value Per Share | -0.17 | -0.28 | -0.64 | -0.33 | 0.35 |